期刊文献+

轻度认知障碍患者血清Tau蛋白及β淀粉样蛋白水平检测的意义 被引量:10

暂未订购
导出
摘要 目的:研究轻度认知障碍(MCI)患者血清中Tau蛋白和β淀粉样蛋白1-42(Aβ1-42)、磷酸化Tau(P-tau)的含量。方法:采用双抗体夹心酶联免疫吸附法检测36例MCI患者,30例老年性痴呆(AD)患者,36例健康者血清中Tau蛋白和β淀粉样蛋白1-42(Aβ1-42)、磷酸化Tau(P-tau)水平。结果:MCI组血清中Tau蛋白浓度与对照组、AD组比较有升高趋势,但差异无统计学意义(P>0.05)。MCI组患者血清中的Aβ1-42与对照组比较明显升高,差异有统计学意义(P<0.05)。对照组患者血清中的Aβ1-42的浓度与AD组比较,差异无统计学意义(P>0.05)。磷酸化Tau(P-tau)蛋白的浓度与对照组、AD组比较差异有统计学意义(P<0.05)。结论:MCI患者血清中Tau蛋白、Aβ1-42、及磷酸化Tau(P-tau)浓度异常情况,与疾病的严重程度相关。
出处 《实用医学杂志》 CAS 北大核心 2012年第4期598-600,共3页 The Journal of Practical Medicine
基金 山东省自然科学基金资助项目(编号:Y2008C125) 山东省教育厅科技计划项目(编号:J08LH67)
  • 相关文献

参考文献13

  • 1王延平,徐桂兰,杨少青,刘湘敏,邓小莹.蒙特利尔认知评估量表识别首次卒中后轻度血管性认知障碍的作用[J].中华神经医学杂志,2010,9(5):503-507. 被引量:52
  • 2施海姗,郑东,孙星海.鼠神经生长因子辅助治疗麻痹性痴呆认知障碍的疗效[J].实用医学杂志,2010,26(15):2810-2812. 被引量:16
  • 3Petersen R C,Smith G E,Waring S C,et al.Mild cognitive:clinical characterization and outcome[J].Arch Neurol,1999,56(3):303-308.
  • 4Andreasen N,Blennow K.CSF biomarkers for mild cognitive impairment and early Alzheimer's disease[J].Clin Neurol Neurosurg,2005,107(3):165-173.
  • 5Fagn A M,Roe C M,Xiong C,et al.Cerebrospinal fluid tau/beta-amy-Loid42 ratio as prediction of cognitive decline in nondemented older a-dults[J].Arch Neurol,2007,64(3):343-349.
  • 6Li G,Sokal I,Quinn J F,et al.CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment:a follow-upstudy[J].Neurology,2007,7(69):631-639.
  • 7Zlokovic B V.Clearing amyloid through the blood-brain barrier.[J].Neuroehem,2004,89(4):807-811.
  • 8Hansson O,Zetterberg H,Vanmechelen E,et al.Evalufion of plasmaAβ40andAβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment[J].Neurobiology Aging,2010,31(3):539-540.
  • 9Lopez O L,KuUer L H,Mehta P D,et al.Plasma amyloid levels and the Risk of AD in normal subjects in the Gardiovascular Healthy Study[J].NeuroLogy,2008,70(19):1664-1671.
  • 10Fukumoto H,Tennis M,Loeaseio J J,et al.Age but not diagnosis is the main predictor of plasma amyloid-protein levels[J].Arch Neuro,2003,60(7):958-964.

二级参考文献23

  • 1邵景范,罗永湘.神经生长因子的载体及其控释系统[J].中华显微外科杂志,1995,18(4):303-305. 被引量:4
  • 2李静,吴馥梅.神经营养因子对认知功能障碍的治疗前景[J].中国生化药物杂志,1995,16(3):143-146. 被引量:9
  • 3郑东,宁玉萍,邓少玲.麻痹性痴呆36例临床分析[J].广州医药,2006,37(4):10-12. 被引量:5
  • 4Andreasen N, Sjogren M, Blennow K. CSF Markers for Alzheimer' s Disease; Total Tau, Phospho2tau and Aβ42 [J]. World Biol Psychiatry, 2003,41 : 147 - 155.
  • 5American Psychiatric Associaton, ed. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: American Psychiatric Association, 1994, 141 - 146.
  • 6Folstein MF. "Mini-mental Sate" a practical method for grading the cognitive state of patients for the clinieian[J]. J Psychiat Res, 1975,12:189 -189.
  • 7Galasko D. Biological markers and the treatment of Alzheimer's disease [J]. J Mol Neurosci, 2001,17:119-125.
  • 8Galasko D. CSF tan and Abeta 42: logical biomarkers for Alzheimer' s disease[J]. Neurobiol Aging, 1998,19:117- 119.
  • 9Et suro M, Mikio S, Koji A, et al. Vascular amyloidosis in neurodegenerative condition [J]. Drugs News Perspect, 2002,15:439-444.
  • 10Thurston VC, ZinkowskiRP, BinderLI.Tau as a nucleolar protein in human nonneural cell in vitro and in vivo[J]. Chromosoma, 1996,105:.20- 30.

共引文献69

同被引文献105

引证文献10

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部